Twenty-four patients were enrolled. Median values for age, time since diagnosis, and number of prior treatments were 63 years, 29 months, and three regimens, respectively. The most common toxicities were hematologic; during the first cycle, median neutrophil and platelet nadirs Read more…
Zoledronic acid administered i.v. at a dosage of 4 mg every 6 months for three doses total was well-tolerated and substantially improved bone mineral density for patients with MGUS and bone loss. Zoledronic acid may be effective for the prevention Read more…
Bortezomib synergizes with melphalan in preclinical and early clinical studies. Updated data from our phase 1/2 study assessing the safety and efficacy of bortezomib plus melphalan in relapsed/refractory multiple myeloma (MM) are presented. Bortezomib (0.7, 1.0, or 1.3 mg/m(2)) on Read more…
Clonidine, idazoxan, and related imidazoline adrenergic drugs bind to non-adrenergic sites in brain and several peripheral tissues. These sites, termed imidazoline receptors, appear to exist in two major subclasses, I1 sites labeled by clonidine and I2 sites labeled by idazoxan. Read more…
Using in vitro autoradiography, mu receptor binding in rat brain was characterized at different amygdala kindling stages and in amygdaloid kindled animals pretreated chronically with naloxone. Male Sprague-Dawley rats implanted with bipolar electrodes in the right amygdala received one of Read more…
The U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (ide-cel) for the treatment of adults with relapsed/refractory multiple myeloma (RRMM) following four or more previous treatments, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Ide-cel Read more…
The combination of pyrotinib plus capecitabine resulted in a statistically significant improvement in progression-free survival compared with lapatinib (Tykerb) plus capecitabine as treatment of patients with previously treated HER2-positive metastatic breast cancer, according to data published in The Lancet Oncology. The Read more…
Preliminary results of a phase 2 study suggest that the addition of the PI3K inhibitor copanlisib to chemotherapy in the first-line setting was not associated with survival benefit in patients with advanced CCA. While chemotherapy with gemcitabine and cisplatin remains the current Read more…
New research suggests that initiating aspirin use in older patients is not associated with a lower risk of colorectal cancer in these individuals. Nevertheless, the pooled analysis of two cohort studies found that people who used aspirin before 70 years of age Read more…
The monoclonal antibody pembrolizumab (Keytruda; Merck) provides statistically significant improvements in progression-free survival relative to standard chemotherapy as first-line treatment in patients with microsatellite-instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer, new research has concluded. Read More…